CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8
Interventions: BIOLOGICAL: Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody
Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)|Imugene Limited